Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-14

Warby Parker Inc. (WRBY) Stock Forecast Oct. 14, 2026

Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE

Follow Unlock full AI forecasts
Rating · 90D ▲ Bullish Exact rating locked
90-day forecast Sign up free to reveal
30-day forecast Total
Rank in coverage Top 35% of 5379 stocks scored
Rank correlation · 90D n/a No per-ticker sample yet
Market Cap $3.28B mid-cap · #4 of 8 peers
Summary

Warby Parker Inc. (WRBY) stock forecast summary

Our AI ranks Warby Parker Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Warby Parker Inc. is a mid-cap company with a market capitalization of $3.28B. It ranks number 4 by market capitalization among the 8 Ophthalmic Goods issuers in our coverage with a current forecast.

A per-ticker accuracy statistic for WRBY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.9% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, WRBY included.

Follow WRBY free
Price

WRBY price chart and AI forecast

WRBY
Cross-section · 2026-10-13

How WRBY ranks among 5379 stocks

90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals

Warby Parker Inc. (WRBY) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Ophthalmic Goods peers listed below that report each metric.

Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.

Valuation & Market

MetricWRBYIndustry medianRank
Market Cap $3.28B $2.31B 4/8
P/E Ratio 423.42x – –
P/B Ratio 9.26x 1.25x 1/7
EPS $0.06 – –
Book Value/Share $2.86 – –
Revenue/Share $7.37 – –
FCF/Share $0.18 – –

Profitability & Margins

MetricWRBYIndustry medianRank
ROIC 0.3% 3.1% 5/6
Gross Margin 54.6% 62.3% 5/6
Operating Margin 0.2% 4.1% 5/6
EBT Margin 1.1% 2.2% 4/6
Tax Rate 21.9% – –

Financial Health

MetricWRBYIndustry medianRank
Current Ratio 2.27x 2.27x 4/7
Quick Ratio 2.01x 2.01x 4/7
D/E Ratio 0.93x 0.52x 3/7
Financial Leverage 1.93x 1.52x 3/7
Interest Coverage 40.6x 3.5x 1/6
Working Capital $207M $247M 5/7

Cash Flow

MetricWRBYIndustry medianRank
Operating Cash Flow $95M $112M 5/8
Free Cash Flow $22M $35M 4/6
Capital Spending -$74M -$77M 3/6
OCF Growth YoY -18.3% – –
FCF Growth YoY -58.5% – –
FCF/Sales 2.4% 2.4% 4/6
CapEx/Sales 8.1% 5.0% 2/6

Operational Efficiency

MetricWRBYIndustry medianRank
Asset Turnover 1.34x 0.46x 1/7
Receivables Turnover 438.3x 6.9x 1/7
Inventory Turnover 9.8x 2.1x 1/6
Fixed Assets Turnover 4.5x 4.9x 5/7
Days Sales Outstanding 1 days 53 days 7/7
Days Inventory 37 days 184 days 6/6
Payables Period 36 days 62 days 4/5
Cash Conversion Cycle 2 days 187 days 5/5

Income Statement

MetricWRBYIndustry medianRank
Total Revenue $911M $911M 4/7
Operating Income $1M $82M 6/7
SG&A Expense $497M $497M 4/7
Cost of Goods Sold $413M $413M 4/7

Dividend & Shareholder Information

MetricWRBYIndustry medianRank
Shares Outstanding 124M – –

Balance Sheet Highlights (USD millions)

Total Current Assets$371M54.3% of assets
Cash & Short-term Investments$293M42.9% of assets
Accounts Receivable$2M0.3% of assets
Inventory$42M6.2% of assets
Total Liabilities$329M48.1% of assets
Short-term Debt$122M17.9% of assets
Quarterly Financial Reports

WRBY quarterly financials and insider trading

Industry Peers · Ophthalmic Goods

Warby Parker Inc. (WRBY) industry peers

Companies classified under the same SEC industry code as Warby Parker Inc. (Ophthalmic Goods): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Total) Market Cap P/E Ratio P/B Ratio
WRBY Warby Parker Inc. ▲ $3.28B 423.4x 9.3x
ALC Alcon Inc ▼ $30.71B – –
COO Cooper Companies, Inc. ▼ $10.38B 18.2x 1.3x
BLCO Bausch & Lomb Corp ▶ $5.65B – 0.9x
EYE National Vision Holdings, Inc. ▼ $1.35B – 1.5x
STAA Staar Surgical Co ▼ $1.08B – 3.0x
RXST Rxsight, Inc. ▲ $188M – 0.7x
LUCY Innovative Eyewear Inc ▲ $7M – 1.1x

Where WRBY sits on the market map

Industrial Applications and Services · Ophthalmic Goods
Explore the map →
News

Warby Parker Inc. (WRBY) stock news

Loading...

FAQ

Warby Parker Inc. (WRBY) stock forecast FAQ

What is the Warby Parker Inc. (WRBY) stock forecast?

Our AI ranks Warby Parker Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

How accurate are Warby Parker Inc. stock predictions?

A per-ticker accuracy statistic for WRBY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Warby Parker Inc. forecasts updated?

Warby Parker Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.

Which companies are Warby Parker Inc.'s industry peers?

8 issuers in our coverage, WRBY included, share the SEC industry code Ophthalmic Goods. The largest are: Alcon Inc (ALC), Cooper Companies, Inc. (COO), Bausch & Lomb Corp (BLCO), National Vision Holdings, Inc. (EYE), Staar Surgical Co (STAA), Rxsight, Inc. (RXST).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.